BIVI
BioVie Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.00
−1.48%Aug 31, 2026, 12:00 UTC
BioVie Inc. completed the treatment phase of its ADDRESS-LC Phase 2 trial of bezisterim for neurological symptoms of Long COVID.
Aug 6, 2026, 11:30 UTC
BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson's disease, showing statistically significant improvements versus placebo on motor and non-motor symptoms.